Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia
نویسندگان
چکیده
منابع مشابه
Corneal Epithelial Microcysts due to High-Dose Cytarabine Administration in a Pediatric Acute Myeloid Leukemia Patient
Over the past 2 decades the advent of new therapeutic strategies has led to remarkable progress in the treatment of acute myeloid leukemia (Aml) [1]; however, some serious side effects of treatment may be clinically apparent [2]. An 8-year-old boy was diagnosed as Aml and started on Aml-BFm 2004 therapy in August 2009. There were no important side effects observed until the initiation of hAm bl...
متن کاملHigh-dose cytarabine induction for acute myeloid leukemia.
In a recent article, Bishop et al’ state that high-dose cytarabine has not previously been used as induction for untreated acute myeloid leukemia (AML). In fact, high-dose cytarabine has been used by itself: with am~acrine,~ and with daunorubicin4 in this role. Additionally, doses of cytarabine significantly above those considered standard had previously been used by other groups for initial in...
متن کاملA randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has been used as a successful salvage and in postremission therapy but not as initial induction treatment. Patients aged 15 to 60 years, presenting with newly diagnosed acute myeloid leukemia (AML) were randomized to receive either high-dose cytarabine, 3 g/m2 12 hourly on days 1, 3, 5, and 7 for 8 doses, dau...
متن کاملHigh-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
The optimal dose, scheme, and clinical setting for Ara-C in acute myeloid leukemia (AML) treatment remain uncertain. In this study, we performed a meta-analysis to systematically assess the impact of high-dose cytarabine (HDAC) on AML therapy during the induction and consolidation stages. Twenty-two trials with a total of 5,945 de novo AML patients were included in the meta-analysis. Only patie...
متن کاملToxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
We are writing to clarify the interpretation of results contained within a paper by Giles et al.1 In their abstract, the authors state, “The [complete remission] CR rate was significantly higher for the laromustine/[high-dose cytarabine] HDAC group (35% vs 19%, P .005). However, the 30-day mortality rate and median progression-free survival were significantly worse in this group compared with H...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Turkish Journal of Hematology
سال: 2012
ISSN: 1300-7777,1308-5263
DOI: 10.5505/tjh.2012.21704